SAM
AQST icon

Strategic Asset Management’s Aquestive Therapeutics AQST Stock Holding History

Strategic Asset Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$0 Hold
50
– – ﹤0.01% 572
2022
Q2 		$0 Hold
50
– – ﹤0.01% 602
2022
Q1 		$0 Hold
50
– – ﹤0.01% 525
2021
Q4 		$0 Hold
50
– – ﹤0.01% 494
2021
Q3 		$0 Buy
+50
New +$196 ﹤0.01% 460

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LI
Latash Investments Anchorage, Alaska $129M AUM 14.69% 1-Year Est. Return

Strategic Asset Management's AQST Position: Q3 2022 in Review

Strategic Asset Management held its Aquestive Therapeutics (AQST) position steady in Q3 2022 at 50 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #572.

Strategic Asset Management first reported a position in AQST in Q3 2021 and has held it in 5 quarters since. 46 funds tracked by Wall St. Rank hold AQST as of Q3 2022.

  • Strategic Asset Management held 50 shares of Aquestive Therapeutics worth $0 as of Q3 2022.
  • Strategic Asset Management left its Aquestive Therapeutics share count unchanged in Q3 2022.
  • Aquestive Therapeutics made up ﹤0.01% of Strategic Asset Management's portfolio in Q3 2022, its #572 holding.
  • Strategic Asset Management first reported a position in Aquestive Therapeutics in Q3 2021 and has held it in 5 quarters since.
  • 46 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2022.

Based on Strategic Asset Management's 13F filing for Q3 2022, filed 1 Nov 2022.